LennerzJKKwakELAckermanAet al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29:4803-4810.
2.
TuynmanJBLagardeSMTen KateFJRichelDJvan LanschotJJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008;98:1102-1108.
3.
AliSMSanfordEMKlempnerSJet al. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. Oncologist. 2015;20:499-507.
4.
KwakELHongTSForcioneDGKambadakoneALennerzJK. Case 35-2016. A 62-year-old man with dysphagia. N Engl J Med. 2016;375:1983-1991.
